571 related articles for article (PubMed ID: 25961136)
1. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
2. Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women.
Cosman F; Nieves JW; Roimisher C; Neubort S; McMahon DJ; Dempster DW; Lindsay R
Bone; 2019 Mar; 120():246-253. PubMed ID: 30355512
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
4. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
5. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
6. Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.
Dempster DW; Cosman F; Zhou H; Nieves JW; Bostrom M; Lindsay R
J Bone Miner Res; 2016 Aug; 31(8):1518-26. PubMed ID: 26916877
[TBL] [Abstract][Full Text] [Related]
7. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Ganapathy A; Nieves JW; Keaveny TM; Cosman F
Bone; 2023 Feb; 167():116618. PubMed ID: 36410666
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
9. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
10. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
12. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
13. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
14. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
Finkelstein JS; Wyland JJ; Lee H; Neer RM
J Clin Endocrinol Metab; 2010 Apr; 95(4):1838-45. PubMed ID: 20164296
[TBL] [Abstract][Full Text] [Related]
15. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.
Cosman F; Lane NE; Bolognese MA; Zanchetta JR; Garcia-Hernandez PA; Sees K; Matriano JA; Gaumer K; Daddona PE
J Clin Endocrinol Metab; 2010 Jan; 95(1):151-8. PubMed ID: 19858319
[TBL] [Abstract][Full Text] [Related]
16. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
[TBL] [Abstract][Full Text] [Related]
17. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Zhang ZL; Liao EY; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; De Peng Y; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L; Santora AC
Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
19. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
[TBL] [Abstract][Full Text] [Related]
20. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
Cohen A; Kamanda-Kosseh M; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; Bucovsky M; Stubby J; Shane E
J Clin Endocrinol Metab; 2015 Nov; 100(11):4208-14. PubMed ID: 26358172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]